



19 March 2021

Company Announcements Office  
Australian Securities Exchange  
Exchange Centre  
20 Bridge Street  
Sydney, NSW 2000

### **Leading Pharmaceutical Executive joins Medlab Board**

- **Seasoned (over 20 years) pharmaceutical experience**
- **Senior global participation (US/Asia)**
- **Medlab structure now matching strategy**

Medlab (ASX:MDC) is an Australian biotech, using delivery platforms to enhance medicines particularly in the field of oncology, is pleased to announce that it has appointed Mrs Cheryl Maley as an Independent Non-Executive Director of the company, effective 19 March 2021.

Mrs Maley is currently a Managing Director of Oncology for global healthcare company Novartis (Australia and New Zealand). She joins the Medlab board with strong pharmaceutical experience including over 20 years in roles across Sales, Marketing, Business Development, Commercial Excellence, Patient Access and General Management.

Mrs Maley is a knowledgeable and multi-functional leader with a proven track record in accelerating and driving long-term strategic growth through innovation, partnering and steering organisational development and projects.

Mrs Maley has a Bachelor of Science Degree, a Diploma of Education, a Masters of Business Administration and is a Graduate of the Australian Institute of Company Directors. She has a passion for innovation and has completed formal innovation training with What-If Innovation (UK), Kellogg Institute (USA), Inventium (Australia) and RAW Innovation (Australia).

"We are delighted to welcome Cheryl to the Board of Medlab Clinical," said Mr Michael Hall, Chairman of Medlab Clinical. "This is an important appointment that broadens the Board's skill set and is aligned with our strategic focus to commercialise novel pharmaceutical products and expand further into overseas markets.

"Cheryl's global focus, especially within her US (Chicago-based for three years) and Asia tenure (Philippines-based for three years) in seeing products through to regulatory approval and knowledge of the oncology market, will be invaluable as we embark on the next stage of our journey".

ENDS

#### **Authorisation & Additional information**

This announcement was authorised by the Board of Directors of Medlab Clinical Limited.

#### **About Medlab – [www.medlab.co](http://www.medlab.co)**

Medlab Clinical is an Australian based medical life science company, developing therapeutic pathways for diagnosed chronic diseases. It is advanced in developing therapies for pain management, depression and obesity as well as earning revenue from sale of nutritional products in Australia and the United States. In pain management Medlab is developing cannabis-based medicines. The Medlab developed nano-particle medicine delivery system, NanoCelle™ is being applied to its medicines, nutritional products and off-patent drugs like statins, Medlab has a growing patent portfolio.

#### **For further information contact:**

Dr Sean Hall, CEO Medlab Clinical T: + 61 2 8203 9520 – <a href="mailto:sean_hall@medlab.co">sean_hall@medlab.co</a>	Kyahn Williamson, WE Communications T: + 61 0401018828 - <a href="mailto:kwilliamson@we-worldwide.com">kwilliamson@we-worldwide.com</a>
---	--